IBI302 8mg dose

Phase 2

Innovent Biologics Inc/ADR (IVBXF)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Aug '26

IVBXFPhase 2$19.2B

IBI302 8mg dose Phase 2 Est. Readout

IBI302 8mg dose• Neovascular Age-related Macular Degeneration800

Aug 2026~Confirmed

CT.gov

00%

Competitive Landscape

3 competitors in Neovascular Age-related Macular Degeneration

Drug Information

Target Indication

Neovascular Age-related Macular Degeneration

Clinical Trial

NCT07275840

Last updated: 6/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

IVBXF

Innovent Biologics Inc/ADR

Biotechnology•North America•NASDAQ

Related Pipeline

IBI301 plus CHOPPhase 3

Diffuse, Large B-Cell, Lymphoma

PicankibartPhase 3

Plaque Psoriasis

DocetaxelPhase 3

HER2-positive Breast Cancer

FebuxostatPhase 3

Gout

IBI311Phase 3

Thyroid Eye Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts